Searching for the “best biotech seed investors” quickly produces lists that combine therapeutic company builders, computational biology investors, laboratory programs, and generalist funds. Those investors can serve different needs. The right shortlist starts with your product and development plan.
This guide is published by Variance Ventures, an investor in the sector. The four external options below were selected for publicly described relevance to early biotechnology or the intersection of biology and technology. They are not ranked by quality, returns, or deal volume. Sources were reviewed on November 9, 2026; confirm current focus and terms directly before pitching.
Four firms and programs to investigate
Fifty Years: pre-seed and seed science companies
Fifty Years describes a pre-seed and seed strategy backing technical founders addressing major problems. Its website features biological manufacturing and diagnostics companies alongside other science and engineering businesses, and offers resources for scientists moving toward company formation.
That makes it worth researching for a founder translating science into a venture-backed business. Read the relevant portfolio examples and identify how your technical and commercial approach fits. The presence of a biology company in a portfolio does not imply interest in every biological application.
NFX Bio: scientist-founders and techbio
NFX Bio describes a thesis around the digitization of biology, AI and machine learning, and automation. It lists bio companies with seed and pre-seed investment stages. NFX’s firm overview also identifies seed and pre-seed as its typical entry stages and describes investment across the US, Israel, Latin America, and Europe.
For a computational biology founder, the useful research question is how the technology changes the experimental or commercial workflow. Explain how the company generates and validates data, rather than assuming an AI label establishes a fit.
2048 Ventures: health, bio, and defensible data
2048’s investment approach includes pre-seed and seed across AI, deep tech, health, and bio, with roots in New York and Boston and investments across the US. Its 2026 fund announcement discusses biological infrastructure, differentiated intellectual property, protein profiling, and automation for drug formulation.
Those are useful signals for founders researching technical biology platforms. A pitch should make the first product and the source of its advantage explicit. Check the current thesis and geographic emphasis instead of treating a broad “biotech VC” label as sufficient.
SOSV SF and SOSV NY: a program-based route
Founders may know these programs under the IndieBio name. The official IndieBio notice explains the change to SOSV SF and SOSV NY in early 2026. SOSV’s investment overview for founders describes entering at pre-seed through its programs.
SOSV SF describes laboratory facilities and expertise across synthetic biology, chemistry, and drug development. SOSV NY describes biology and deep tech investing, including therapeutic development. Evaluate the program format, location expectations, facilities, and current terms alongside the investment. That is a different decision from selecting a passive financial participant.
How to use “top” and “most active” lists
“Top” is useful only when the criteria are clear. A fund may fit your stage but lack experience in the development path you face. A prominent clinical investor may be less relevant to a research software company than a smaller tools-focused fund.
“Most active biotech investors” requires a dated dataset, a defined geography, and a consistent treatment of new investments versus follow-ons. This guide does not make that ranking. Use activity lists as discovery tools, then verify the specific partner, subsector, and financing role.
Our investor activity research guide explains the evidence and counting rules to look for.
Where Variance Ventures fits
Variance invests at pre-seed and seed, primarily in the US while considering founders globally. Typical initial checks are around $50,000, with flexibility. Our biotechnology focus covers the convergence of computation and biology within our six-sector mandate. A smaller check should be considered in the context of the full financing plan and any specialist expertise the company needs.
Before outreach, build a milestone plan that connects experiments, dependencies, budget, and the next decision. Our small-check investor guide covers round composition. If the fit is relevant, send Variance your pitch with the scientific insight, current evidence, team, and capital requirements.